Trials / Completed
CompletedNCT01903928
A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant
An Open Phase 2 Trial to Evaluate Safety of a Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in subjects undergoing allogeneic HCT. The occurrence of CMV viremia and immunogenicity are also assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ASP0113 | injection |
Timeline
- Start date
- 2013-06-20
- Primary completion
- 2015-01-19
- Completion
- 2015-01-19
- First posted
- 2013-07-19
- Last updated
- 2024-10-17
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01903928. Inclusion in this directory is not an endorsement.